

Special Issue

Decoding Resistance: Molecular Drivers of Therapy Failure in Advanced Prostate Cancer

Message from the Guest Editor

Castration-resistant prostate cancer (CRPC), particularly in its metastatic form (mCRPC), represents one of the most prevalent and lethal malignancies among men worldwide. Managing CRPC is challenging due to intrinsic or acquired resistance to therapy, driven by complex, multifactorial mechanisms that limit long-term treatment efficacy. The progression from hormone-sensitive prostate cancer (HSPC) to CRPC marks a pivotal clinical transition, underscored by resistance to androgen deprivation therapy (ADT) and the emergence of more aggressive, treatment-refractory phenotypes. Advances in molecular and immunological perspectives are rapidly reshaping the treatment landscape for mHSPC and mCRPC, underscoring the urgent need to unravel resistance mechanisms to develop more effective, personalized therapies. This Special Issue aims to highlight cutting-edge research elucidating the molecular and cellular mechanisms underpinning resistance to ADT, second-generation anti-androgens, radiotherapy, and novel targeted therapies.

Guest Editor

Dr. Jyoti Kaushal

Radiation Oncology, College of Medicine, Fred & Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/247913

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).